Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 922 participants.

Also called NCT04023227

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 922 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04023227
Other papers using this trial's data
  • Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial JAMA, 2026-01-06 DOI, PubMed 41335448, PMC12676478 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Argentina, Brazil, Colombia, Mexico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04023227. Randomized; single masking; primary purpose treatment. Start 2019-12-10 (actual); primary completion 2025-03-16 (actual). Results posted on 2026-05-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC
Acronym
PARACHUTE-HF
Condition
Chagas Disease
Condition
Heart Failure
Intervention (Drug)
Sacubitril/valsartan
Intervention (Drug)
Enalapril
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct04023227
Content hash
c3a3515b8e54bd61efbc7d3c96246ebae3140b25589406b2c75a6239a2f631a6